Date: 2013-07-31
Type of information: Grant
Company: Summit (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £2.4 million (€2.75 million)
Funding type: grant
Planned used: The grant will support the clinical development of Summit’s utrophin modulator drug SMT C1100 for the treatment of Duchenne Muscular Dystrophy.
Others: * On July 31, 2013, Summit, a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announces that it has been awarded a grant of £2.4 million from the UK Biomedical Catalyst Fund. The grant will support the future development of SMT C1100 by contributing towards the Phase 1b and Phase 2 clinical trials in DMD patients, long-term toxicology studies and the development of novel biomarkers for use in the Phase 2 clinical trial. The aim of this clinical programme is to establish the safety and efficacy of SMT C1100 and validate utrophin modulation as a viable therapy with the potential to treat all DMD patients.
Therapeutic area: Rare diseases - Neuromuscular diseases
